Management of bone metastases in cancer: a review.

[1]  R. Coleman.  Bisphosphonates in breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Scully,et al.  Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  F. Saad,et al.  Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.

[4]  I. Holen,et al.  Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion , 2005, Anti-cancer drugs.

[5]  J. Berenson.  Recommendations for zoledronic acid treatment of patients with bone metastases. , 2005, The oncologist.

[6]  A. Patwardhan,et al.  Balloon kyphoplasty for the treatment of pathological vertebral compressive fractures , 2005, European Spine Journal.

[7]  A. Heidenreich,et al.  Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease , 2004, Expert review of anticancer therapy.

[8]  R. Bell,et al.  Profiling the safety and tolerability of bisphosphonates. , 2004, Seminars in oncology.

[9]  R. Coleman.  Bisphosphonates: clinical experience. , 2004, The oncologist.

[10]  Naoto T Ueno,et al.  Bone imaging in metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Hillner,et al.  American society of clinical oncology 2003 update on the role of biophosphonates and bone health issues in women with breast cancer , 2004 .

[12]  K. Broadley,et al.  Systematic review of bisphosphonates for hypercalcaemia of malignancy , 2004, Palliative medicine.

[13]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[14]  J. Herndon,et al.  Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. , 2004, Lung cancer.

[15]  R. Sciuto,et al.  153Sm-EDTMP for bone pain palliation in skeletal metastases , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[17]  H. Schirrmeister,et al.  Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  D. Tripathy,et al.  Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies , 2004, British Journal of Cancer.

[19]  G. Y. Wong,et al.  Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Kotzerke,et al.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain , 2004, Journal of Cancer Research and Clinical Oncology.

[21]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[24]  I. Tannock,et al.  Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  S. Johnston,et al.  Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer , 2003, BMJ : British Medical Journal.

[27]  M. Krzakowski,et al.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Crispino,et al.  Effect of the Combination of Docetaxel, Zoledronic Acid, and a COX-2 Inhibitor on the Growth of Human Breast Cancer Cell Lines , 2003, American journal of clinical oncology.

[29]  G. Oades,et al.  Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. , 2003, The Journal of urology.

[30]  K. Mohammad,et al.  Role of endothelin‐1 in osteoblastic bone metastases , 2003, Cancer.

[31]  K. Ahrar,et al.  Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients , 2003 .

[32]  D. Podoloff,et al.  Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[33]  R. Vessella,et al.  Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  J. Gralow.  Bisphosphonates as adjuvant treatment for breast cancer , 2002, British medical journal.

[35]  S. Ralston,et al.  Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma , 2002, British journal of haematology.

[36]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[37]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Chirgwin,et al.  Transforming Growth Factor-Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways * , 2002 .

[39]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[40]  S. Yang,et al.  Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer , 2002, Journal of Cancer Research and Clinical Oncology.

[41]  J. Nelson,et al.  Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Rogers,et al.  Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption , 2002 .

[43]  Paul J. Williams,et al.  Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. , 2002, Cancer research.

[44]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[45]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[46]  F. Saad,et al.  The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.

[47]  M. Stajszczyk.  [Bisphosphonates in the treatment of multiple myeloma]. , 2002, Przeglad lekarski.

[48]  M. Johnston,et al.  Meta-analysis of single-fraction versus multi-fraction radiotherapy trials for palliation of painful bone metastases , 2001 .

[49]  A. Howell,et al.  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.

[50]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[51]  Paul J. Williams,et al.  The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. , 2001, Cancer research.

[52]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[53]  P. Croucher,et al.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel , 2001, British Journal of Cancer.

[54]  Sera An.  Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis , 2001 .

[55]  J. Hopper,et al.  Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. , 2001, Journal of the National Cancer Institute.

[56]  C. Poulter,et al.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.

[57]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Brown,et al.  Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. , 2000, Endocrinology.

[60]  A. Evans,et al.  Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. , 2000, Clinical radiology.

[61]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.

[62]  D. Finkelstein,et al.  Predictors of skeletal complications in patients with metastatic breast carcinoma , 2000, Cancer.

[63]  A. McEwan,et al.  Use of radionuclides for the palliation of bone metastases. , 2000, Seminars in radiation oncology.

[64]  G. Pirianov,et al.  Bisphosphonates induce apoptosis in human breast cancer cell lines , 2000, British Journal of Cancer.

[65]  B. Hillner,et al.  American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .

[66]  P. Strang,et al.  89Strontium in the management of painful sceletal metastases. , 2000, Anticancer Research.

[67]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[68]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[69]  J. Chirgwin,et al.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.

[70]  M. Pecherstorfer,et al.  Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy , 1999, Drug safety.

[71]  J Kotzerke,et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[72]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[73]  Nielsen Os.  Palliative radiotherapy of bone metastases: there is now evidence for the use of single fractions. , 1999 .

[74]  J Kievit,et al.  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[75]  J. Mönkkönen,et al.  Molecular mechanisms of action of bisphosphonates. , 1999, Bone.

[76]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[78]  G. Hortobagyi,et al.  Markers of bone resorption in patients treated with pamidronate. , 1998, European journal of cancer.

[79]  F. Fulfaro,et al.  The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials , 1998, Pain.

[80]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[81]  C. Proukakis,et al.  Strontium-89 Chloride in the Treatment of Bone Metastases from Breast Cancer , 1998, Oncology.

[82]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[83]  M. Rogers,et al.  Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[84]  G. Mundy.  Myeloma bone disease. , 1998, European journal of cancer.

[85]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[87]  R. Rubens,et al.  Clinical course and prognostic factors following bone recurrence from breast cancer. , 1998, British Journal of Cancer.

[88]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[89]  R. Coleman.  Skeletal complications of malignancy , 1997, Cancer.

[90]  D. Rosenthal.  Radiologic diagnosis of bone metastases , 1997, Cancer.

[91]  R. Rubens,et al.  A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. , 1997, European journal of cancer.

[92]  M. Koizumi,et al.  Dissociation of bone formation markers in bone metastasis of prostate cancer. , 1997, British Journal of Cancer.

[93]  C. Rudenstam,et al.  Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study. , 1999, Acta oncologica.

[94]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[95]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[96]  J. Bonneterre,et al.  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  H. Vloedgraven,et al.  Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.

[98]  R. Eastell,et al.  Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.

[99]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[100]  G. Mundy,et al.  Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. , 1996, Cancer research.

[101]  V. Chinchilli,et al.  Biochemical markers of bone turnover in patients with metastatic bone disease. , 1995, Clinical chemistry.

[102]  S. Ralston,et al.  Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[104]  C. Koopman,et al.  Pain and depression in patients with cancer , 1994, Cancer.

[105]  S. Rabbani,et al.  Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.

[106]  K. Anderson,et al.  Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma , 1994, The Lancet.

[107]  C. Bucca,et al.  Bisphosphonate-induced bronchoconstriction In aspirin-sensitive asthma , 1994, The Lancet.

[108]  E. Seregni,et al.  Bone scintigraphy in breast cancer: a ten-year follow-up study. , 1993, Journal of nuclear biology and medicine.

[109]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  G. Hortobagyi.  Bone metastases in breast cancer patients. , 1991, Seminars in oncology.

[111]  A. McEwan,et al.  A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. , 1991, European journal of cancer.

[112]  A. Perruchoud,et al.  Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. , 1991, Thorax.

[113]  J. Hayman,et al.  Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. , 1991, Cancer research.

[114]  O. S. Nielsen,et al.  Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J L Bloem,et al.  Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. , 1991, Radiographics : a review publication of the Radiological Society of North America, Inc.

[116]  H. Mirels.  Metastatic Disease in Long Bones A Proposed Scoring System for Diagnosing Impending Pathologic Fractures , 1989, Clinical orthopaedics and related research.

[117]  Y. Ichinose,et al.  Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages 1 and 2 non-small cell lung cancer. Preoperative examination for lung cancer. , 1989, Chest.

[118]  W. Smoker,et al.  Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. , 1987, Neurosurgery.

[119]  R. Rubens,et al.  The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.

[120]  Paterson Ah.  Bone metastases in breast cancer, prostate cancer and myeloma. , 1987 .

[121]  D. E. Jackson,et al.  Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans. , 1986, Chest.

[122]  B. Gainor,et al.  A Profile of Metastatic Carcinoma of the Spine , 1985, Spine.

[123]  F. Sim,et al.  Methylmethacrylate as an adjunct in internal fixation of pathological fractures. Experience with three hundred and seventy-five cases. , 1976, The Journal of bone and joint surgery. American volume.